Filing Flows › Ironwood Pharmaceuticals (IRWD) › Q3 2026 › vs Q3 2025
Ironwood Pharmaceuticals (IRWD) Q3 2026 vs Q3 2025 (year over year)
Ironwood Pharmaceuticals's revenue rose $11.0M (+9%) from $122M in Q3 2025 to $133M in Q3 2026. Operating margin 70.0% against 61.8% (+8.2 pts).
Ironwood Pharmaceuticals, Q3 2026: revenue $133M (+9% year over year), operating margin 70.0%, net earnings $59.8M, operating cash flow $67.4M. The chart draws each line against Q3 2025, the increases inside each band.
Margins
| Q3 2026 | Q3 2025 | Change | |
|---|---|---|---|
| Operating margin | 70.0% | 61.8% | +8.2 pts |
| Net margin | 45.0% | 32.8% | +12.1 pts |
Every line
| Line | Q3 2026 | Q3 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $133M | $122M | $11.0M | +9% |
| Operating profit | $93.1M | $75.5M | $17.6M | +23% |
| Costs & expenses | $39.9M | $46.6M | −$6.7M | -14% |
| Pre-tax earnings | $87.6M | $68.0M | $19.6M | +29% |
| Other expense, net | $5.5M | $7.5M | −$1.9M | -26% |
| Research & development | $28.4M | $22.5M | $5.9M | +26% |
| SG&A | $11.6M | $21.9M | −$10.4M | -47% |
| Net earnings | $59.8M | $40.1M | $19.8M | +49% |
| Income tax | $27.8M | $27.9M | −$182K | -0.7% |
| Depreciation | $459K | $475K | −$16K | -3% |
| Share-based compensation | $4.3M | $3.6M | $679K | +19% |
| Working capital & other | $2.8M | $3.4M | −$603K | -18% |
| Operating cash flow | $67.4M | $47.6M | $19.8M | +42% |
Questions
How much did Ironwood Pharmaceuticals's revenue grow year over year in Q3 2026?
Ironwood Pharmaceuticals's revenue rose $11.0M (+9%) from $122M in Q3 2025 to $133M in Q3 2026. Operating margin 70.0% against 61.8% (+8.2 pts).